We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Constellation's (STZ) Brand Sale to Aid Wine & Spirits Business
Read MoreHide Full Article
Constellation Brands Inc. (STZ - Free Report) successfully closed its previously agreed-upon deal to divest a portion of Constellation’s wine and spirits portfolio to E. & J. Gallo Winery. The transaction included Constellation’s brands priced at $11 retail and below, including certain related facilities located in California, New York, and Washington State.
As part of the deal, the company paid an aggregate of $810 million to Gallo, including about $560 million of cash payment on closing and the prospect to receive up to $250 million in earnout payments, depending on the fulfillment of brand performance targets within a two-year period after closing. Moreover, the transaction price includes adjustments of nearly $220 million related to changes in inventory for which Constellation already received the benefit.
Simultaneously, the company sealed its separate but related deal with Gallo to sell the New Zealand-based Nobilo Wine brand and related assets and liabilities for $130 million. Additionally, it completed the divestiture of certain brands, related inventory, interests in contracts and liabilities of its grape juice concentrate business to Vie-Del Company.
Meanwhile, the company received approval for the sale of the Paul Masson Grande Amber Brandy brand, related inventory and interests in certain contracts to Sazerac for $255 million. The transaction is likely to be completed in January 2021.
With the sale of the aforementioned assets and brands, the company expects accelerated revenue and operating margin performance at its wine and spirits business. Going forward, it expects to gain from the persistence of premiumization trends in the market. Notably, the divestitures position it well to gain from the premiumization trends through the crafting of a winning portfolio of distinguishing high-end brands.
Lately, Constellation’s wine & spirits premiumization strategy is playing out well, as evident from accelerated growth for the Power Brands and strong margin performance in second-quarter fiscal 2021. Notably, the company’s higher-end wine power brands outpaced the U.S. high-end wine category in IRI channels. This growth was led by gains in Kim Crawford, Meiomi and The Prisoner Brand Family, all of which reported double-digit growth in IRI channels.
Additionally, the company is making investments to fuel growth of its power brands through innovation, capitalizing on priority, consumer trends, with successful product introductions. Some of the recently introduced products are the Prisoner Cabernet Sauvignon and Chardonnay varietals, SVEDKA and High West ready-to-drink cocktails, Ruffino wine spritzer, and Meiomi Cabernet Sauvignon.
Shares of the leading alcohol company have gained 19.4% in the past three months compared with the industry’s growth of 15.4%. The company currently carries a Zacks Rank #3 (Hold).
Coca-Cola European Partners PLC’s (CCEP - Free Report) Zacks Consensus Estimate for 2021 earnings has gone up 1.9% in the past 60 days. It currently carries a Zacks Rank #2.
Molson Coors Beverage Company (TAP - Free Report) , also a Zacks Rank #2 stock, has an expected long-term earnings growth rate of 3.7%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Constellation's (STZ) Brand Sale to Aid Wine & Spirits Business
Constellation Brands Inc. (STZ - Free Report) successfully closed its previously agreed-upon deal to divest a portion of Constellation’s wine and spirits portfolio to E. & J. Gallo Winery. The transaction included Constellation’s brands priced at $11 retail and below, including certain related facilities located in California, New York, and Washington State.
As part of the deal, the company paid an aggregate of $810 million to Gallo, including about $560 million of cash payment on closing and the prospect to receive up to $250 million in earnout payments, depending on the fulfillment of brand performance targets within a two-year period after closing. Moreover, the transaction price includes adjustments of nearly $220 million related to changes in inventory for which Constellation already received the benefit.
Simultaneously, the company sealed its separate but related deal with Gallo to sell the New Zealand-based Nobilo Wine brand and related assets and liabilities for $130 million. Additionally, it completed the divestiture of certain brands, related inventory, interests in contracts and liabilities of its grape juice concentrate business to Vie-Del Company.
Meanwhile, the company received approval for the sale of the Paul Masson Grande Amber Brandy brand, related inventory and interests in certain contracts to Sazerac for $255 million. The transaction is likely to be completed in January 2021.
With the sale of the aforementioned assets and brands, the company expects accelerated revenue and operating margin performance at its wine and spirits business. Going forward, it expects to gain from the persistence of premiumization trends in the market. Notably, the divestitures position it well to gain from the premiumization trends through the crafting of a winning portfolio of distinguishing high-end brands.
Lately, Constellation’s wine & spirits premiumization strategy is playing out well, as evident from accelerated growth for the Power Brands and strong margin performance in second-quarter fiscal 2021. Notably, the company’s higher-end wine power brands outpaced the U.S. high-end wine category in IRI channels. This growth was led by gains in Kim Crawford, Meiomi and The Prisoner Brand Family, all of which reported double-digit growth in IRI channels.
Additionally, the company is making investments to fuel growth of its power brands through innovation, capitalizing on priority, consumer trends, with successful product introductions. Some of the recently introduced products are the Prisoner Cabernet Sauvignon and Chardonnay varietals, SVEDKA and High West ready-to-drink cocktails, Ruffino wine spritzer, and Meiomi Cabernet Sauvignon.
Shares of the leading alcohol company have gained 19.4% in the past three months compared with the industry’s growth of 15.4%. The company currently carries a Zacks Rank #3 (Hold).
Key Beverage Stocks to Watch
The Boston Beer Company, Inc. (SAM - Free Report) delivered an earnings surprise of 23.1%, on average, in the trailing four quarters. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Coca-Cola European Partners PLC’s (CCEP - Free Report) Zacks Consensus Estimate for 2021 earnings has gone up 1.9% in the past 60 days. It currently carries a Zacks Rank #2.
Molson Coors Beverage Company (TAP - Free Report) , also a Zacks Rank #2 stock, has an expected long-term earnings growth rate of 3.7%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>